SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
38.93
+0.14 (+0.36%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close38.79
Open39.03
Bid38.39 x 1000
Ask38.41 x 3100
Day's Range38.86 - 39.17
52 Week Range37.43 - 50.65
Volume991,233
Avg. Volume1,194,711
Market Cap96.977B
Beta0.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.86 (4.64%)
Ex-Dividend Date2018-05-09
1y Target Est47.67
Trade prices are not sourced from all markets
  • GlobeNewswire21 hours ago

    FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

    The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. “If approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by adults with type 1 diabetes, in combination with insulin,” says Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi.

  • PR Newswire21 hours ago

    FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

    BRIDGEWATER, N.J. and THE WOODLANDS, Texas, May 22, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. "If approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by adults with type 1 diabetes, in combination with insulin." says Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi.

  • 3 Warren Buffett Stocks With Dividend Yields Over 4%
    Motley Fool23 hours ago

    3 Warren Buffett Stocks With Dividend Yields Over 4%

    But are these high-yielding stocks in the billionaire investor's portfolio smart picks for the rest of us?

  • GlobeNewswire2 days ago

    Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

    Press Release   Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent ® (dupilumab) improved moderate-to-severe asthma Results ...

  • PR Newswire2 days ago

    New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

    * In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo. * Results showed ...

  • Motley Fool2 days ago

    Is This European Drug Stock Giant a Buy?

    Here's an international healthcare stock to consider for your portfolio.

  • Moody's5 days ago

    AI Sirona (Luxembourg) Acquisition S.a.r.l. -- Moody's assigns Al Sirona Acquisition (Zentiva) a first-time rating of B3; outlook stable

    Moody's Investors Service, ("Moody's") has today assigned a first-time B3 corporate family rating (CFR) and a B3-PD Probability of Default Rating (PDR) to Al Sirona (Luxembourg) Acquisition S.a.r.l. ...

  • Motley Fool5 days ago

    Don’t Ignore European Healthcare Stocks

    International healthcare stocks could be a great fit for your portfolio.

  • 5 Companies To Watch As Marijuana Legalization Approaches
    Oilprice.com6 days ago

    5 Companies To Watch As Marijuana Legalization Approaches

    Canada is about to become the first major industrialized nation to legalize marijuana use across the country, and the companies that have positioned themselves to profit could see remarkable gains

  • TheStreet.com7 days ago

    Trump Administration Rolls Out Shaming as Drug Pricing Tool

    President Trump took heat for being too soft on drug companies in a speech last week. The Centers for Medicare and Medicaid Services on Tuesday, May 15, rolled out revamped Drug Spending Dashboards that likely will put pressure on drug companies to lower prices. The newly designed dashboards show how much is spent in Medicare Part B, Medicare Part D and Medicaid for name-brand drugs.

  • Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
    Zacks7 days ago

    Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

    Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

  • AstraZeneca’s 1Q18 Estimates: CVMD Products
    Market Realist7 days ago

    AstraZeneca’s 1Q18 Estimates: CVMD Products

    AstraZeneca’s (AZN) Cardiovascular and Metabolic Disease (or CVMD) segment includes various products such as Brilinta, Farxiga, Bydureon, Byetta, Onglyza, and Symlin and legacy products such as Atacand, Crestor, and Seloken.

  • PR Newswire7 days ago

    Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

    PARIS and TARRYTOWN, N.Y., May 16, 2018 /PRNewswire/ -- A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints. Dupixent is the first and only biologic to show positive results in this patient population. "Moderate-to-severe atopic dermatitis can place a particularly significant burden on adolescents, who have to deal with oozing skin lesions with unrelenting, intense itching during their formative years," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.

  • ACCESSWIRE7 days ago

    Wired News – Sanofi and Ablynx Announce Results of the Initial Tender Offer Period and Commencement of Squeeze-Out Tender Period

    LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want access to our free research report on Sanofi American Depositary Shares (NYSE: SNY) ("Sanofi"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SNY as the Company's latest news hit the wire. On May 14, 2018, the Company along with Ablynx NV (NASDAQ: ABLX) together reported the successful results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares, including shares represented by American Depositary Shares (ADSs), warrants, and convertible bonds of Ablynx.

  • Bloomberg7 days ago

    Luxury Stocks Are Reshaping France's CAC 40

    A year ago LVMH, the owner of luxury brand Louis Vuitton, became France’s biggest company by market value, a mantle energy giant Total SA and drugmaker Sanofi SA had shared for almost a decade. Kering SA was nowhere in sight. A more than 200 percent rally since the start of 2016, and more than 70 percent over the past 12 months, has now put the owner of “it bag” brands within shouting distance of the top five stocks in the CAC 40 Index.

  • GlobeNewswire7 days ago

    Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

    May 16, 2018 - A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints. Dupixent is the first and only biologic to show positive results in this patient population. "Moderate-to-severe atopic dermatitis can place a particularly significant burden on adolescents, who have to deal with oozing skin lesions with unrelenting, intense itching during their formative years," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.

  • Layoffs hit Framingham corporate giants Staples, TJX, Genzyme
    American City Business Journals8 days ago

    Layoffs hit Framingham corporate giants Staples, TJX, Genzyme

    Genzyme recently cut 95 jobs in Framingham, while TJX and Staples, both headquartered in the city, have slashed a combined 477 workers in undisclosed locations.

  • PR Newswire8 days ago

    It Affects Over 1.5 Million People in the UK. , In a Survey, 80% Report that it Impacts their Mood, Mental Health and Well-Being. But What is Atopic Dermatitis?

    Launching today, Scratch Beneath the Surface is a new UK public health initiative created by Sanofi in collaboration with leading national charity, Allergy UK. By improving awareness of atopic dermatitis, Scratch Beneath the Surface hopes to shift any misconceptions among the general public and combat the stigma related to the disease, which will in turn, lead to those affected feeling a greater sense of support and understanding.

  • The Likely 5 Winners Of Canada’s Cannabis Boom
    Oilprice.com8 days ago

    The Likely 5 Winners Of Canada’s Cannabis Boom

    The marijuana market in North America is growing at an astounding rate, with investors who are in the know set to reap most of the rewards

  • Is Sanofi’s (NYSE:SNY) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.9 days ago

    Is Sanofi’s (NYSE:SNY) Balance Sheet Strong Enough To Weather A Storm?

    Investors pursuing a solid, dependable stock investment can often be led to Sanofi (NYSE:SNY), a large-cap worth US$94.36B. Doing business globally, large caps tend to have diversified revenue streams andRead More...

  • GlobeNewswire9 days ago

    Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period

        Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period ...

  • Merck and AstraZeneca Announced EMA Approval for Lynparza
    Market Realist15 days ago

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

  • Investopedia15 days ago

    Warren Buffett's 10 Big Stock Losers

    Warren Buffett is widely recognized as the greatest investor in the world, based on a decades-long record of outperformance, but he's the first to acknowledge that he's merely mortal, with more than his share of mistakes. The Oracle of Omaha announced in 2018 that Berkshire Hathaway completely exited its IBM position.

  • How Repatha Is Positioned after 1Q18
    Market Realist15 days ago

    How Repatha Is Positioned after 1Q18

    In 1Q18, Amgen’s (AMGN) Repatha revenue grew 15% YoY (year-over-year) to $123 million from $49 million, primarily due to higher unit demand. It grew ~26% quarter-over-quarter. In US and international markets, Repatha generated revenue of $84 million and $39 million, respectively, compared with $33 million and $16 million in 1Q17.

  • Alimta: An Emerging Drug to Treat Lung Cancer
    Market Realist16 days ago

    Alimta: An Emerging Drug to Treat Lung Cancer

    On April 30, the FDA granted priority review status to the sBLA (supplemental biologics license application) seeking approval for the combination of Merck’s (MRK) Keytruda, Eli Lilly’s (LLY) Alimta, and platinum-based chemotherapy agents like carboplatin or cisplatin in first-line metastatic NSCLC (non-squamous non-small cell lung cancer) indication. The Prescription Drug User Fee Act’s date is September 23. The sBLA is based on data from the Phase 3 KEYNOTE-189 trial declared on April 16. ...